Sionna Therapeutics (SION) Preferred Stock Liabilities (2024)
Quarterly results put Preferred Stock Liabilities at $330.4 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $330.4 million (changed N/A YoY), and the annual figure for FY2024 was $330.4 million, changed.
Sionna Therapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $330.4 million for Q4 2024.
- Preferred Stock Liabilities reached $330.4 million in Q4 2024 per SION's latest filing, up from $181.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $330.4 million in Q4 2024 and bottomed at $13.0 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Sionna Therapeutics | 1.87 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 330.37 Mn |
| Sep 30, 2024 | 181.33 Mn |
| Jun 30, 2024 | 13.01 Mn |
| Mar 31, 2024 | 110.79 Mn |